Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet. The Ajax acquisition was a ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

File photo first issued 06/11/25 by the Ministry of Defence of an AJAX Armoured Fighting Vehicle (AFV). MPs have questioned whether the Army's troubled £6.3 billion Ajax light tank will ever be fit ...

Add Yahoo as a preferred source to see more of our stories on Google. The Ajax was seen in its first public running display at Tankfest 2024 at The Tank Museum in Dorset, but problems quickly emerged ...

As our economy, society and daily life become increasingly dependent on data, new college graduates entering the workforce need to have the skills to analyze data effectively and from multiple angles.

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Trials of the British Army’s Ajax armoured vehicles are set to resume, despite major delays amid concern for soldiers’ safety. Minister for Defence Readiness and Industry Luke Pollard announced in ...

Trials of the British Army's Ajax armoured vehicle will be "proceeding cautiously" after they were halted last year, a defence minister has said. A decision was made to stop using the Ajax after ...

LONDON, April 28 (Reuters) - Britain's defence readiness minister Luke Pollard said he had agreed to restart the army's acceptance of Ajax armoured vehicles from General Dynamics with ‌strict controls ...

General Dynamics said the safety of soldiers 'is, and has always been, our highest priority'. Trials of the Army's troubled Ajax armoured vehicles will resume "cautiously", with the defence minister ...

Eli Lilly LLY-1.21%decrease; down pointing triangle continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...